676 related articles for article (PubMed ID: 24022075)
21. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
Liu J; Wang L; Zhao F; Tseng S; Narayanan C; Shura L; Willingham S; Howard M; Prohaska S; Volkmer J; Chao M; Weissman IL; Majeti R
PLoS One; 2015; 10(9):e0137345. PubMed ID: 26390038
[TBL] [Abstract][Full Text] [Related]
22. Novel antibodies in the treatment of non-Hodgkin's lymphoma.
Bhat SA; Czuczman MS
Neth J Med; 2009 Sep; 67(8):311-21. PubMed ID: 19767657
[TBL] [Abstract][Full Text] [Related]
23. Rituximab immunotherapy for non-Hodgkin's lymphoma.
White CA
Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
[TBL] [Abstract][Full Text] [Related]
24. Optimization of anti-CD20 humanized antibody hu8E4 by site-directed mutation based on epitope analysis.
Chen Y; Chen L; Lu Q; Meng Y; Wang C; Wang L; Wang H; Yu X; Zhang Y; Zhao L; Li B; Guo Y
Biochem Biophys Res Commun; 2015 Apr; 459(4):617-22. PubMed ID: 25749344
[TBL] [Abstract][Full Text] [Related]
25. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
Bornstein GG; Quéva C; Tabrizi M; van Abbema A; Chavez C; Wang P; Foord O; Ahluwalia K; Laing N; Raja S; Wen S; Green LL; Yang X; Webster C; Stewart R; Blakey D
Invest New Drugs; 2010 Oct; 28(5):561-74. PubMed ID: 19626278
[TBL] [Abstract][Full Text] [Related]
26. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101.
Dalle S; Reslan L; Besseyre de Horts T; Herveau S; Herting F; Plesa A; Friess T; Umana P; Klein C; Dumontet C
Mol Cancer Ther; 2011 Jan; 10(1):178-85. PubMed ID: 21220500
[TBL] [Abstract][Full Text] [Related]
27. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S85-90. PubMed ID: 11587374
[TBL] [Abstract][Full Text] [Related]
28. The future of CD20 monoclonal antibody therapy in B-cell malignancies.
Czuczman MS; Gregory SA
Leuk Lymphoma; 2010 Jun; 51(6):983-94. PubMed ID: 20367564
[TBL] [Abstract][Full Text] [Related]
29. [Monoclonal antibody immunotherapy for malignant non-Hodgkin's lymphoma].
Jourdan E; Richard B
Presse Med; 2000 Apr; 29(13):717-21. PubMed ID: 10797826
[TBL] [Abstract][Full Text] [Related]
30. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.
Mössner E; Brünker P; Moser S; Püntener U; Schmidt C; Herter S; Grau R; Gerdes C; Nopora A; van Puijenbroek E; Ferrara C; Sondermann P; Jäger C; Strein P; Fertig G; Friess T; Schüll C; Bauer S; Dal Porto J; Del Nagro C; Dabbagh K; Dyer MJ; Poppema S; Klein C; Umaña P
Blood; 2010 Jun; 115(22):4393-402. PubMed ID: 20194898
[TBL] [Abstract][Full Text] [Related]
31. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.
Klein C; Lammens A; Schäfer W; Georges G; Schwaiger M; Mössner E; Hopfner KP; Umaña P; Niederfellner G
MAbs; 2013; 5(1):22-33. PubMed ID: 23211638
[TBL] [Abstract][Full Text] [Related]
32. Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates.
Leonard JP
Hematology Am Soc Hematol Educ Program; 2005; ():335-9. PubMed ID: 16304400
[TBL] [Abstract][Full Text] [Related]
33. Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice.
Smith MR; Joshi I; Jin F; Obasaju C
BMC Cancer; 2005 Aug; 5():103. PubMed ID: 16109167
[TBL] [Abstract][Full Text] [Related]
34. A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL-2Rγ(null) mouse lymphoma model.
Sato F; Ito A; Ishida T; Mori F; Takino H; Inagaki A; Ri M; Kusumoto S; Komatsu H; Iida S; Okada N; Inagaki H; Ueda R
Cancer Immunol Immunother; 2010 Dec; 59(12):1791-800. PubMed ID: 20714721
[TBL] [Abstract][Full Text] [Related]
35. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
Braza MS; Klein B; Fiol G; Rossi JF
Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
[TBL] [Abstract][Full Text] [Related]
36. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
[TBL] [Abstract][Full Text] [Related]
37. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.
Winiarska M; Bojarczuk K; Pyrzynska B; Bil J; Siernicka M; Dwojak M; Bobrowicz M; Miazek N; Zapala P; Zagozdzon A; Krol M; Syta A; Podszywalow-Bartnicka P; Pilch Z; Dabrowska-Iwanicka A; Juszczynski P; Efremov DG; Slabicki M; Zenz T; Le Roy A; Olive D; Rygiel TP; Leusen JH; Golab J
MAbs; 2014; 6(5):1300-13. PubMed ID: 25517315
[TBL] [Abstract][Full Text] [Related]
38. Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab.
Golay J; Gramigna R; Facchinetti V; Capello D; Gaidano G; Introna M
Br J Haematol; 2002 Dec; 119(4):923-9. PubMed ID: 12472569
[TBL] [Abstract][Full Text] [Related]
39. Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMab.
Zhao L; Xie F; Tong X; Li H; Chen Y; Qian W; Duan S; Zheng J; Zhao Z; Li B; Zhang D; Zhao J; Dai J; Wang H; Hou S; Guo Y
MAbs; 2014; 6(3):740-8. PubMed ID: 24670986
[TBL] [Abstract][Full Text] [Related]
40. [Advances in the research of anti-CD20 therapeutic monoclonal antibodies].
Deng CL; Zou J; Song HF
Yao Xue Xue Bao; 2013 Oct; 48(10):1515-20. PubMed ID: 24417077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]